Cholinergic agonists reduce blood pressure in a mouse model of systemic lupus erythematosus

Amber S. Fairley, Keisa Mathis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Increased inflammation arising from an abnormal immune response can damage healthy tissue and lead to disease progression. An important example of this is the accumulation of inflammatory mediators in the kidney, which can subsequently lead to hypertension and renal injury. The origin of this inflammation may involve neuro-immune interactions. For example, the novel vagus nerve-to-spleen mechanism known as the “cholinergic anti-inflammatory pathway” controls inflammation upon stimulation. However, if this pathway is dysfunctional, inflammation becomes less regulated and chronic inflammatory diseases such as hypertension may develop. Systemic lupus erythematosus (SLE) is an autoimmune disease with aberrant immune function, increased renal inflammation, and prevalent hypertension. We hypothesized that the cholinergic anti-inflammatory pathway is impaired in SLE and that stimulation of this pathway would protect from the progression of hypertension in SLE mice. Female SLE (NZBWF1) and control (NZW) mice were administered nicotine or vehicle for 7 days (2 mg/kg/day, subcutaneously) in order to stimulate the cholinergic anti-inflammatory pathway at the level of the splenic nicotinic acetylcholine receptor (α7-nAChR). Blood pressure was assessed posttreatment. Nicotine-treated SLE mice did not develop hypertension and this lower blood pressure (compared to saline-treated SLE mice) coincided with lower splenic and renal cortical expression of pro-inflammatory cytokines. These data provide evidence that the cholinergic anti-inflammatory pathway is impaired in SLE. In addition, these data suggest that stimulation of the cholinergic anti-inflammatory pathway can protect the kidney by dampening inflammation and therefore prevent the progression of hypertension in the setting of SLE.

Original languageEnglish
Article numbere13213
JournalPhysiological Reports
Volume5
Issue number7
DOIs
StatePublished - 1 Apr 2017

Fingerprint

Cholinergic Agonists
Systemic Lupus Erythematosus
Blood Pressure
Cholinergic Agents
Inflammation
Anti-Inflammatory Agents
Hypertension
Kidney
Nicotine
Renal Hypertension
Vagus Nerve
Nicotinic Receptors
Autoimmune Diseases
Disease Progression
Chronic Disease
Spleen
Cytokines
Wounds and Injuries

Keywords

  • Cholinergic anti-inflammatory pathway
  • hypertension
  • inflammation
  • kidney
  • nicotine
  • renal injury

Cite this

@article{7279d00bfc9b4dabae1833df263e995f,
title = "Cholinergic agonists reduce blood pressure in a mouse model of systemic lupus erythematosus",
abstract = "Increased inflammation arising from an abnormal immune response can damage healthy tissue and lead to disease progression. An important example of this is the accumulation of inflammatory mediators in the kidney, which can subsequently lead to hypertension and renal injury. The origin of this inflammation may involve neuro-immune interactions. For example, the novel vagus nerve-to-spleen mechanism known as the “cholinergic anti-inflammatory pathway” controls inflammation upon stimulation. However, if this pathway is dysfunctional, inflammation becomes less regulated and chronic inflammatory diseases such as hypertension may develop. Systemic lupus erythematosus (SLE) is an autoimmune disease with aberrant immune function, increased renal inflammation, and prevalent hypertension. We hypothesized that the cholinergic anti-inflammatory pathway is impaired in SLE and that stimulation of this pathway would protect from the progression of hypertension in SLE mice. Female SLE (NZBWF1) and control (NZW) mice were administered nicotine or vehicle for 7 days (2 mg/kg/day, subcutaneously) in order to stimulate the cholinergic anti-inflammatory pathway at the level of the splenic nicotinic acetylcholine receptor (α7-nAChR). Blood pressure was assessed posttreatment. Nicotine-treated SLE mice did not develop hypertension and this lower blood pressure (compared to saline-treated SLE mice) coincided with lower splenic and renal cortical expression of pro-inflammatory cytokines. These data provide evidence that the cholinergic anti-inflammatory pathway is impaired in SLE. In addition, these data suggest that stimulation of the cholinergic anti-inflammatory pathway can protect the kidney by dampening inflammation and therefore prevent the progression of hypertension in the setting of SLE.",
keywords = "Cholinergic anti-inflammatory pathway, hypertension, inflammation, kidney, nicotine, renal injury",
author = "Fairley, {Amber S.} and Keisa Mathis",
year = "2017",
month = "4",
day = "1",
doi = "10.14814/phy2.13213",
language = "English",
volume = "5",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

Cholinergic agonists reduce blood pressure in a mouse model of systemic lupus erythematosus. / Fairley, Amber S.; Mathis, Keisa.

In: Physiological Reports, Vol. 5, No. 7, e13213, 01.04.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cholinergic agonists reduce blood pressure in a mouse model of systemic lupus erythematosus

AU - Fairley, Amber S.

AU - Mathis, Keisa

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Increased inflammation arising from an abnormal immune response can damage healthy tissue and lead to disease progression. An important example of this is the accumulation of inflammatory mediators in the kidney, which can subsequently lead to hypertension and renal injury. The origin of this inflammation may involve neuro-immune interactions. For example, the novel vagus nerve-to-spleen mechanism known as the “cholinergic anti-inflammatory pathway” controls inflammation upon stimulation. However, if this pathway is dysfunctional, inflammation becomes less regulated and chronic inflammatory diseases such as hypertension may develop. Systemic lupus erythematosus (SLE) is an autoimmune disease with aberrant immune function, increased renal inflammation, and prevalent hypertension. We hypothesized that the cholinergic anti-inflammatory pathway is impaired in SLE and that stimulation of this pathway would protect from the progression of hypertension in SLE mice. Female SLE (NZBWF1) and control (NZW) mice were administered nicotine or vehicle for 7 days (2 mg/kg/day, subcutaneously) in order to stimulate the cholinergic anti-inflammatory pathway at the level of the splenic nicotinic acetylcholine receptor (α7-nAChR). Blood pressure was assessed posttreatment. Nicotine-treated SLE mice did not develop hypertension and this lower blood pressure (compared to saline-treated SLE mice) coincided with lower splenic and renal cortical expression of pro-inflammatory cytokines. These data provide evidence that the cholinergic anti-inflammatory pathway is impaired in SLE. In addition, these data suggest that stimulation of the cholinergic anti-inflammatory pathway can protect the kidney by dampening inflammation and therefore prevent the progression of hypertension in the setting of SLE.

AB - Increased inflammation arising from an abnormal immune response can damage healthy tissue and lead to disease progression. An important example of this is the accumulation of inflammatory mediators in the kidney, which can subsequently lead to hypertension and renal injury. The origin of this inflammation may involve neuro-immune interactions. For example, the novel vagus nerve-to-spleen mechanism known as the “cholinergic anti-inflammatory pathway” controls inflammation upon stimulation. However, if this pathway is dysfunctional, inflammation becomes less regulated and chronic inflammatory diseases such as hypertension may develop. Systemic lupus erythematosus (SLE) is an autoimmune disease with aberrant immune function, increased renal inflammation, and prevalent hypertension. We hypothesized that the cholinergic anti-inflammatory pathway is impaired in SLE and that stimulation of this pathway would protect from the progression of hypertension in SLE mice. Female SLE (NZBWF1) and control (NZW) mice were administered nicotine or vehicle for 7 days (2 mg/kg/day, subcutaneously) in order to stimulate the cholinergic anti-inflammatory pathway at the level of the splenic nicotinic acetylcholine receptor (α7-nAChR). Blood pressure was assessed posttreatment. Nicotine-treated SLE mice did not develop hypertension and this lower blood pressure (compared to saline-treated SLE mice) coincided with lower splenic and renal cortical expression of pro-inflammatory cytokines. These data provide evidence that the cholinergic anti-inflammatory pathway is impaired in SLE. In addition, these data suggest that stimulation of the cholinergic anti-inflammatory pathway can protect the kidney by dampening inflammation and therefore prevent the progression of hypertension in the setting of SLE.

KW - Cholinergic anti-inflammatory pathway

KW - hypertension

KW - inflammation

KW - kidney

KW - nicotine

KW - renal injury

UR - http://www.scopus.com/inward/record.url?scp=85017556904&partnerID=8YFLogxK

U2 - 10.14814/phy2.13213

DO - 10.14814/phy2.13213

M3 - Article

C2 - 28400502

AN - SCOPUS:85017556904

VL - 5

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 7

M1 - e13213

ER -